Clinical Characteristics and Prognostic Risk Factors in Breast Cancer With Liver Metastasis
The Breast Journal · 2026-01 · 2026 (1)
DOI: 10.1155/tbj/5088737 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Breast Journal, online erschienen am 20.06.2026. Verfasst von Dandan Yu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China, njmu.edu.cn. Hauptthemen laut MEDLINE: Liver Neoplasms, Breast Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Nanjing Medical University.
Abstract (Originalsprache)
Background
Liver metastasis is a key adverse prognostic factor in breast cancer patients. This research was aimed to assess the development, risk factors, and prognostic determinants of breast cancer liver metastasis (BCLM).
Methods
We retrospectively analyzed the data of breast cancer from the Surveillance, Epidemiology, and End Results (SEER) ( N = 560,908) and Jiangsu Province Hospital (JSPH) database ( N = 294). The risk factors for BCLM were identified via multivariate logistic regression, and overall survival (OS) was assessed with Kaplan–Meier (KM) survival curves and Cox regression models.
Results
In the SEER cohort, liver metastasis attacked 1.3% of patients, and the highest incidence was found in the HR−/HER2+ subtype (4.4%). The risk factors for BCLM include young age, high pathological grade, concurrent bone, lung or brain metastasis, and HER2‐positive or triple‐negative subtype. The median OS of BCLM patients was short (SEER: 22 months; JSPH: 33.5 months). OS was shorter in patients with concomitant metastasis to other organs or with HER2‐negative subtype. Hepatic resection remarkably prolonged survival (SEER: 90 vs. 35 months; JSPH: not reached vs. 31.3 months). In the JSPH cohort, molecular subtype changed in 27.5% of patients during metastasis.
Conclusions
The occurrence of BCLM is affected by age, tumor grade, other organ involvement, and molecular subtype. Survival was improved in BCLM patients with liver‐only metastasis, HER2‐positive subtype, or those who underwent hepatic resection. The number and molecular characteristics of liver metastasis are important prognostic predictors, and receptor conversion highlights the need for reassessment of therapeutic strategies during metastatic progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China, njmu.edu.cn.
- Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China, njmu.edu.cn.
- Department of Breast Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China, njmu.edu.cn.
- Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Personalized Cancer Medicine, Nanjing Medical University, Nanjing, 210029, China, njmu.edu.cn.
ORCID-Profile: Dandan Yu, Dandan Wang, Xiaoxiang Guan
Förderung
- National Natural Science Foundation of China
- Nanjing Medical University
Zitieren
APA
Yu, D., Zhu, C., Yang, S., Wang, D., & Guan, X. (2026). Clinical Characteristics and Prognostic Risk Factors in Breast Cancer With Liver Metastasis. The Breast Journal, 2026(1). https://doi.org/10.1155/tbj/5088737
Vancouver
Yu D, Zhu C, Yang S, Wang D, Guan X. Clinical Characteristics and Prognostic Risk Factors in Breast Cancer With Liver Metastasis. The Breast Journal. 2026;2026(1). doi:10.1155/tbj/5088737
BibTeX
@article{Yu2026,
author = {Yu, Dandan and Zhu, Chengjun and Yang, Sujin and Wang, Dandan and Guan, Xiaoxiang},
title = {Clinical Characteristics and Prognostic Risk Factors in Breast Cancer With Liver Metastasis},
journal = {The Breast Journal},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/tbj/5088737}
}
EUVIMED